A multi-institutional evaluation of active surveillance for low risk prostate cancer

Scott E. Eggener, Alex Mueller, Ryan K. Berglund, Raj Ayyathurai, Cindy Soloway, Mark S. Soloway, Robert Abouassaly, Eric A. Klein, Steven J. Jones, Chris Zappavigna, Larry Goldenberg, Peter T. Scardino, James A. Eastham, Bertrand Guillonneau

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Purpose: For select men with low risk prostate cancer active surveillance is more often being considered a management strategy. In a multicenter retrospective study we evaluated the actuarial rates and predictors of remaining on active surveillance, the incidence of cancer progression and the pathological findings of delayed radical prostatectomy. Materials and Methods: A cohort of 262 men from 4 institutions met the inclusion criteria of age 75 years or younger, prostate specific antigen 10 ng/ml or less, clinical stage T1-T2a, biopsy Gleason sum 6 or less, 3 or less positive cores at diagnostic biopsy, repeat biopsy before active surveillance and no treatment for 6 months following the repeat biopsy. Active surveillance started on the date of the second biopsy. Actuarial rates of remaining on active surveillance were calculated and univariate Cox regression was used to assess predictors of discontinuing active surveillance. Results: With a median followup of 29 months 43 patients ultimately received active treatment. The 2 and 5-year probabilities of remaining on active surveillance were 91% and 75%, respectively. Patients with cancer on the second biopsy (HR 2.23, 95% CI 1.23-4.06, p = 0.007) and a higher number of cancerous cores from the 2 biopsies combined (p = 0.002) were more likely to undergo treatment. Age, prostate specific antigen, clinical stage, prostate volume and number of total biopsy cores sampled were not predictive of outcome. Skeletal metastases developed in 1 patient 38 months after starting active surveillance. Of the 43 patients undergoing delayed treatment 41 (95%) are without disease progression at a median of 23 months following treatment. Conclusions: With a median followup of 29 months active surveillance for select patients appears to be safe and associated with a low risk of systemic progression. Cancer at restaging biopsy and a higher total number of cancerous cores are associated with a lower likelihood of remaining on active surveillance. A restaging biopsy should be strongly considered to finalize eligibility for active surveillance.

Original languageEnglish
JournalJournal of Urology
Volume189
Issue number1 SUPPL
DOIs
StatePublished - Jan 1 2013
Externally publishedYes

Fingerprint

Prostatic Neoplasms
Biopsy
Prostate-Specific Antigen
Therapeutics
Second Primary Neoplasms
Prostatectomy
Multicenter Studies
Disease Progression
Prostate
Neoplasms
Retrospective Studies
Neoplasm Metastasis
Incidence

Keywords

  • biopsy
  • prostatic neoplasms
  • treatment outcome

ASJC Scopus subject areas

  • Urology

Cite this

Eggener, S. E., Mueller, A., Berglund, R. K., Ayyathurai, R., Soloway, C., Soloway, M. S., ... Guillonneau, B. (2013). A multi-institutional evaluation of active surveillance for low risk prostate cancer. Journal of Urology, 189(1 SUPPL). https://doi.org/10.1016/j.juro.2012.11.023

A multi-institutional evaluation of active surveillance for low risk prostate cancer. / Eggener, Scott E.; Mueller, Alex; Berglund, Ryan K.; Ayyathurai, Raj; Soloway, Cindy; Soloway, Mark S.; Abouassaly, Robert; Klein, Eric A.; Jones, Steven J.; Zappavigna, Chris; Goldenberg, Larry; Scardino, Peter T.; Eastham, James A.; Guillonneau, Bertrand.

In: Journal of Urology, Vol. 189, No. 1 SUPPL, 01.01.2013.

Research output: Contribution to journalArticle

Eggener, SE, Mueller, A, Berglund, RK, Ayyathurai, R, Soloway, C, Soloway, MS, Abouassaly, R, Klein, EA, Jones, SJ, Zappavigna, C, Goldenberg, L, Scardino, PT, Eastham, JA & Guillonneau, B 2013, 'A multi-institutional evaluation of active surveillance for low risk prostate cancer', Journal of Urology, vol. 189, no. 1 SUPPL. https://doi.org/10.1016/j.juro.2012.11.023
Eggener SE, Mueller A, Berglund RK, Ayyathurai R, Soloway C, Soloway MS et al. A multi-institutional evaluation of active surveillance for low risk prostate cancer. Journal of Urology. 2013 Jan 1;189(1 SUPPL). https://doi.org/10.1016/j.juro.2012.11.023
Eggener, Scott E. ; Mueller, Alex ; Berglund, Ryan K. ; Ayyathurai, Raj ; Soloway, Cindy ; Soloway, Mark S. ; Abouassaly, Robert ; Klein, Eric A. ; Jones, Steven J. ; Zappavigna, Chris ; Goldenberg, Larry ; Scardino, Peter T. ; Eastham, James A. ; Guillonneau, Bertrand. / A multi-institutional evaluation of active surveillance for low risk prostate cancer. In: Journal of Urology. 2013 ; Vol. 189, No. 1 SUPPL.
@article{f9b37330ec044fbfaf988fc72b64287a,
title = "A multi-institutional evaluation of active surveillance for low risk prostate cancer",
abstract = "Purpose: For select men with low risk prostate cancer active surveillance is more often being considered a management strategy. In a multicenter retrospective study we evaluated the actuarial rates and predictors of remaining on active surveillance, the incidence of cancer progression and the pathological findings of delayed radical prostatectomy. Materials and Methods: A cohort of 262 men from 4 institutions met the inclusion criteria of age 75 years or younger, prostate specific antigen 10 ng/ml or less, clinical stage T1-T2a, biopsy Gleason sum 6 or less, 3 or less positive cores at diagnostic biopsy, repeat biopsy before active surveillance and no treatment for 6 months following the repeat biopsy. Active surveillance started on the date of the second biopsy. Actuarial rates of remaining on active surveillance were calculated and univariate Cox regression was used to assess predictors of discontinuing active surveillance. Results: With a median followup of 29 months 43 patients ultimately received active treatment. The 2 and 5-year probabilities of remaining on active surveillance were 91{\%} and 75{\%}, respectively. Patients with cancer on the second biopsy (HR 2.23, 95{\%} CI 1.23-4.06, p = 0.007) and a higher number of cancerous cores from the 2 biopsies combined (p = 0.002) were more likely to undergo treatment. Age, prostate specific antigen, clinical stage, prostate volume and number of total biopsy cores sampled were not predictive of outcome. Skeletal metastases developed in 1 patient 38 months after starting active surveillance. Of the 43 patients undergoing delayed treatment 41 (95{\%}) are without disease progression at a median of 23 months following treatment. Conclusions: With a median followup of 29 months active surveillance for select patients appears to be safe and associated with a low risk of systemic progression. Cancer at restaging biopsy and a higher total number of cancerous cores are associated with a lower likelihood of remaining on active surveillance. A restaging biopsy should be strongly considered to finalize eligibility for active surveillance.",
keywords = "biopsy, prostatic neoplasms, treatment outcome",
author = "Eggener, {Scott E.} and Alex Mueller and Berglund, {Ryan K.} and Raj Ayyathurai and Cindy Soloway and Soloway, {Mark S.} and Robert Abouassaly and Klein, {Eric A.} and Jones, {Steven J.} and Chris Zappavigna and Larry Goldenberg and Scardino, {Peter T.} and Eastham, {James A.} and Bertrand Guillonneau",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.juro.2012.11.023",
language = "English",
volume = "189",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "1 SUPPL",

}

TY - JOUR

T1 - A multi-institutional evaluation of active surveillance for low risk prostate cancer

AU - Eggener, Scott E.

AU - Mueller, Alex

AU - Berglund, Ryan K.

AU - Ayyathurai, Raj

AU - Soloway, Cindy

AU - Soloway, Mark S.

AU - Abouassaly, Robert

AU - Klein, Eric A.

AU - Jones, Steven J.

AU - Zappavigna, Chris

AU - Goldenberg, Larry

AU - Scardino, Peter T.

AU - Eastham, James A.

AU - Guillonneau, Bertrand

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: For select men with low risk prostate cancer active surveillance is more often being considered a management strategy. In a multicenter retrospective study we evaluated the actuarial rates and predictors of remaining on active surveillance, the incidence of cancer progression and the pathological findings of delayed radical prostatectomy. Materials and Methods: A cohort of 262 men from 4 institutions met the inclusion criteria of age 75 years or younger, prostate specific antigen 10 ng/ml or less, clinical stage T1-T2a, biopsy Gleason sum 6 or less, 3 or less positive cores at diagnostic biopsy, repeat biopsy before active surveillance and no treatment for 6 months following the repeat biopsy. Active surveillance started on the date of the second biopsy. Actuarial rates of remaining on active surveillance were calculated and univariate Cox regression was used to assess predictors of discontinuing active surveillance. Results: With a median followup of 29 months 43 patients ultimately received active treatment. The 2 and 5-year probabilities of remaining on active surveillance were 91% and 75%, respectively. Patients with cancer on the second biopsy (HR 2.23, 95% CI 1.23-4.06, p = 0.007) and a higher number of cancerous cores from the 2 biopsies combined (p = 0.002) were more likely to undergo treatment. Age, prostate specific antigen, clinical stage, prostate volume and number of total biopsy cores sampled were not predictive of outcome. Skeletal metastases developed in 1 patient 38 months after starting active surveillance. Of the 43 patients undergoing delayed treatment 41 (95%) are without disease progression at a median of 23 months following treatment. Conclusions: With a median followup of 29 months active surveillance for select patients appears to be safe and associated with a low risk of systemic progression. Cancer at restaging biopsy and a higher total number of cancerous cores are associated with a lower likelihood of remaining on active surveillance. A restaging biopsy should be strongly considered to finalize eligibility for active surveillance.

AB - Purpose: For select men with low risk prostate cancer active surveillance is more often being considered a management strategy. In a multicenter retrospective study we evaluated the actuarial rates and predictors of remaining on active surveillance, the incidence of cancer progression and the pathological findings of delayed radical prostatectomy. Materials and Methods: A cohort of 262 men from 4 institutions met the inclusion criteria of age 75 years or younger, prostate specific antigen 10 ng/ml or less, clinical stage T1-T2a, biopsy Gleason sum 6 or less, 3 or less positive cores at diagnostic biopsy, repeat biopsy before active surveillance and no treatment for 6 months following the repeat biopsy. Active surveillance started on the date of the second biopsy. Actuarial rates of remaining on active surveillance were calculated and univariate Cox regression was used to assess predictors of discontinuing active surveillance. Results: With a median followup of 29 months 43 patients ultimately received active treatment. The 2 and 5-year probabilities of remaining on active surveillance were 91% and 75%, respectively. Patients with cancer on the second biopsy (HR 2.23, 95% CI 1.23-4.06, p = 0.007) and a higher number of cancerous cores from the 2 biopsies combined (p = 0.002) were more likely to undergo treatment. Age, prostate specific antigen, clinical stage, prostate volume and number of total biopsy cores sampled were not predictive of outcome. Skeletal metastases developed in 1 patient 38 months after starting active surveillance. Of the 43 patients undergoing delayed treatment 41 (95%) are without disease progression at a median of 23 months following treatment. Conclusions: With a median followup of 29 months active surveillance for select patients appears to be safe and associated with a low risk of systemic progression. Cancer at restaging biopsy and a higher total number of cancerous cores are associated with a lower likelihood of remaining on active surveillance. A restaging biopsy should be strongly considered to finalize eligibility for active surveillance.

KW - biopsy

KW - prostatic neoplasms

KW - treatment outcome

UR - http://www.scopus.com/inward/record.url?scp=84870889258&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870889258&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2012.11.023

DO - 10.1016/j.juro.2012.11.023

M3 - Article

VL - 189

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 1 SUPPL

ER -